100XBIO: Funding, Investors & Team (Sep 2026)
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to revolutionize a market currently reliant on time-consuming manual processes. This platform not only addresses the $3 billion market for T-cell research crucial to advancing treatments in areas like oncology and infectious disease, but also unlocks new opportunities in the immune diagnostics market valued at over $40 billion.
100XBIO has raised $110k across 4 funding rounds on record, the most recent a Pre-Seed announced in Dec 2025.
100XBIO Company Profile and Key Stats
Latest funding round on record: Dec 2025.
100XBIO Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
100XBIO raised $20k in an undisclosed round announced in Mar 2024.
4 months later, a Pre-Seed of $30k was announced in Jul 2024.
9 months later, a Pre-Seed of $60k was announced in Apr 2025.
8 months later, a Pre-Seed was announced in Dec 2025 with no disclosed amount.
100XBIO Founders and Leadership Team
Contact details for the 100XBIO team: 1 of 1 has an email address on file.
Start 14-day free trial →100XBIO Funding Compared to Other Biotechnology Startups
Funded Startups Like 100XBIO in Biotechnology and Woburn
Companies Similar to 100XBIO
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
100XBIO Funding FAQs
What does 100XBIO do?
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to revolutionize a market currently reliant on time-consuming manual processes. This platform not only addresses the $3 billion market for T-cell research crucial to advancing treatments in areas like oncology and infectious disease, but also unlocks new opportunities in the immune diagnostics market valued at over $40 billion.
How much funding has 100XBIO raised?
100XBIO has raised $110k across 4 rounds on record.
When did 100XBIO last raise funding?
100XBIO's most recent funding round on record was announced in Dec 2025. The amount was not disclosed.
Who founded 100XBIO?
FundedIQ lists Sergei Pustylnikov (Founder) at 100XBIO.
Where is 100XBIO headquartered?
100XBIO is based in Woburn, Massachusetts, United States.
How many employees does 100XBIO have?
100XBIO is in the 1-10 employee band.
About FundedIQ's 100XBIO Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 100XBIO is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.